Quadrature Capital
PRME icon

Quadrature Capital’s Prime Medicine PRME Stock Holding History

Quadrature Capital’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$161K Sell
43,663
-3,230
-7% -$10.7K ﹤0.01% 1401
2026
Q1 		$163K Sell
46,893
-5,973
-11% -$22.7K ﹤0.01% 1159
2025
Q4 		$183K Buy
52,866
+42,684
+419% +$190K ﹤0.01% 994
2025
Q3 		$56.3K Buy
+10,182
New +$41.4K ﹤0.01% 946
2025
Q2 		– Sell
-24,802
Closed -$49.6K – 1391
2025
Q1 		$49.6K Buy
+24,802
New +$63.3K ﹤0.01% 977

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Quadrature Capital's PRME Position: Q2 2026 in Review

Quadrature Capital reduced its Prime Medicine (PRME) stake by 6.9% in Q2 2026, selling an estimated $10.7K and leaving 43,663 shares worth $161K. The position accounts for ﹤0.01% of the portfolio, ranked #1401.

Quadrature Capital first reported a position in PRME in Q1 2025 and has held it in 5 quarters since. The position peaked at $183K in Q4 2025. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Quadrature Capital held 43,663 shares of Prime Medicine worth $161K as of Q2 2026.
  • Quadrature Capital sold 3,230 Prime Medicine shares in Q2 2026, an estimated $10.7K.
  • Prime Medicine made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1401 holding.
  • Quadrature Capital first reported a position in Prime Medicine in Q1 2025 and has held it in 5 quarters since.
  • Quadrature Capital's Prime Medicine position peaked at $183K in Q4 2025.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.